B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients

Diabetes and Metabolism

Volumn 34, Issue 4, 2008, Pages 355-362

  Albertini, J P ^a   Cohen, R ^a   Valensi, P ^b   Sachs, R N ^a   Charniot, J C ^a  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

B type natriuretic peptide; Echocardiography; Left ventricular dysfunction; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPID;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; DISEASE MARKER; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE PRESSURE; SYSTOLIC DYSFUNCTION; URINARY EXCRETION;

AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 51849117175     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.02.004     Document Type: Article

References (32)

1. Kannel W.B., Hjorland M., and Castelli W.P. Role of diabetes in congestive heart failure. The Framingham study. Am J Cardiol 34 (1974) 29-34
2. Shindler D.M., Kostis J.B., Yusuf S., Quinones M.A., Pitt B., Stewart D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD), trials and registry. Am J Cardiol 77 (1996) 1017-1020
3. Wingard D.L., and Barret-Connor E. Heart disease and diabetes in diabetes in America. 2nd ed. (1995), National Institutes of Health, Bethesda, National Institute of Diabetes and Digestive and Kidney Disease, National Diabetes Data Group 429-448
4. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101 (2000) 2271-2276
5. Cohen A., Ederhy S., and Boccara F. Left ventricular diastolic (dys)function in type 2 diabetes: time for a critical reappraisal. Diabetes Metab 33 (2007) 1-2
6. Dargie H.J., and McMurray J.J. Diagnosis and management of heart failure. BMJ 308 (1994) 321-328
7. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
8. Yoshimura M., Yasue H., Morita E., Sakaino N., Jougasaki M., Kurose M., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
9. Maisel A.S., Koon J., Krishnaswamy P., Kazenegra R., Clopton P., Gardetto N., et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141 (2001) 367-374
10. Hogenhuis J., Voors A.A., Jaarsma T., Hillege H.L., Boomsma F., and van Veldhuisen D.J. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 7 (2005) 81-86
11. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Wilson P.W., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
12. Mark D.B., and Felker G.M. B-type natriuretic peptide: A biomarker for all seasons?. N Engl J Med 350 (2004) 718-720
13. Tarnow L., Hildebrandt P., Hansen B.V., Borch-Johnsen K., and Parving H.H. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 48 (2005) 149-155
14. Gaede P., Hildebrandt P., Hess G., Parving H.H., and Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48 (2005) 156-163
15. Yano Y., Katsuki A., Gabazza E.C., Ito K., Fujii M., Furuta M., et al. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84 (1999) 2353-2356
16. Asakawa H., Fukui T., Tokunaga K., and Kawakami F. Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease and microalbuminuria. J Diabetes Complicat 16 (2002) 209-213
17. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 27 suppl 1 (2004) S65-S67
18. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., and Quinones M.A. No evidence for left ventricular diastolic dysfunction in asymptomatic normotensive type 2 diabetic patients: a case-control study with new echocardiographic techniques. J Am Coll Cardiol 30 (1997) 1527-1533
19. Chan N.N., and Hurel S.J. Brain natriuretic peptide as a potential marker of diastolic dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 2019-2020
20. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
21. Epshteyn V., Morrison K., Krishnaswamy P., Kazanegra R., Clopton P., Mudaliar S., et al. Utility of B-Type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26 (2003) 2081-2087
22. Ritz E. Albuminuria and vascular damage the vicious twins. N Engl J Med 348 (2003) 2349-2352
23. Franklin S.S., Khan S.A., Wong N.D., Larson M.G., and Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 100 (1999) 354-360
24. Dunn E.J., and Grant P.J. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 5 (2005) 323-332
25. Kathiresan S., Gona P., Larson M.G., Vita J.A., Mitchell G.F., Tofler Gh, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 113 (2006) 938-945
26. Cosson E., Pham I., Valensi P., Pariès J., Attali J.R., and Nitenberg A. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 29 (2006) 107-112
27. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., and Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110 (2004) 1794-1798
28. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. Circulation 108 (2003) 684-690
29. Devereux R.B., Dahlof B., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol. Circulation 110 (2004) 146-162
30. Olsen M.H., Wachtell K., Tuxen C., Fossum E., Bang L.E., Hall C., et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy. J Hypertens 23 (2005) 1083-1090
31. Cosson S., Kevorkian J.-P., Virally M.-L., Henry P., Laloi-Michelin M., Meas T., et al. No evidence for left ventricular diastolic dysfunction in asymptomatic normotensive type 2 diabetic patients: a case-control study with new echocardiographic techniques. Diabetes Metab 33 (2007) 61-67
32. Valle R., Bagolin E., Canali C., Giovinazzo P., Barro S., Aspromonte N., et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr 7 (2006) 40-44